Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
No Benefit from More than 3 Months of Adjuvant Oxaliplatin in Colon Cancer
Extending oxaliplatin treatment beyond 3 months offers no survival benefit.
A New Therapeutic Option for BCG-Unresponsive Bladder Cancer
An immune-cell–activating interleukin-15 superagonist led to a complete response in 71% of patients.
Mapping the Remarkable Complexity of Chronic Lymphocytic Leukemia
Striking molecular heterogeneity was identified using multiparametric analysis of a large cohort of patients with CLL.
Racial Disparities in iTTP Outcomes
Black race was associated with higher relapse risk, even after adjusting for treatment with rituximab and selection bias.
Capecitabine–Temozolomide Therapy for Pancreatic Neuroendocrine Tumors
Encouraging rates of response, progression-free survival, and overall survival were seen with this combination therapy compared with temozolomide alone.
A New Regimen for Pediatric Hodgkin Lymphoma
Children and adolescents with advanced-stage disease had superior outcomes when brentuximab vedotin was added to chemotherapy and risk-adapted radiation therapy.
Lobular and Ductal Breast Cancer: How Do They Differ?
A retrospective study showed that overall survival is worse with invasive lobular carcinoma, among other key differences in outcomes and clinicopathologic features.
Adjuvant Pembrolizumab for Resected NSCLC
Disease-free survival was improved with pembrolizumab compared with placebo after complete resection and adjuvant chemotherapy.
Bemarituzumab for FGFR2b-Positive Gastric Cancer
Bemarituzumab, a monoclonal antibody that blocks FGFR2b, was active in patients with FGFR2b overexpression or FGFR2 gene amplification in a phase 2 study.